Urology News and Research

Latest Urology News and Research

Signostics gets FDA 510k clearance for handheld bladder scanner

Medical device company, Signostics, announced today it has clearance from the U.S. Food and Drug Administration to launch the SignosRT Bladder, the company’s new hand-held bladder scanner.

15 Jan 2015

ArborMetrix's RegistryMetrix analytics platform selected for UNC's urology department

ArborMetrix, Inc., a leading provider of cloud-based healthcare analytics solutions, today announced that the Urology Department of the University of North Carolina School of Medicine is using its cloud-based RegistryMetrix analytics platform.

15 Jan 2015

Study demonstrates that pelvic floor muscle training improves erectile function

Preliminary results of a four-month clinical trial offer hope for the thousands of baby boomer men turning 50 every minute, with nearly 6-in-10 of them experiencing erectile dysfunction. Proving pelvic floor exercise can help turn back the clock on sexual decline, the study demonstrates that weighted resistance training improves erectile function in both healthy men and those with erectile dysfunction.

12 Jan 2015

New imaging technique measurably improves prostate cancer screening

In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men. Writing in the January 6, 2015 issue of the journal Prostate Cancer and Prostatic Disease, a team of scientists and physicians from the University of California, San Diego School of Medicine, with counterparts at University of California, Los Angeles, describe a novel imaging technique that measurably improves upon current prostate imaging - and may have significant implications for how patients with prostate cancer are ultimately treated.

6 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Laparoscopic radical cystectomy can lead to reliable, long-term cancer control

Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to a study published in BJU International. The findings, which come from the largest study to date with long-term follow-up after this type of minimally invasive surgery, indicate that prospective randomized trials comparing these two bladder cancer surgeries are warranted.

18 Dec 2014

Olympus receives FDA clearance for Narrow Band Imaging

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today FDA 510(k) clearance of Narrow Band Imaging (NBI) as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor boundaries in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients.

From Evident Corporation - Life Sciences 15 Dec 2014

Study: Patients with operable kidney cancers more likely to have partial nephrectomy

Patients with operable kidney cancers were more likely to have a partial nephrectomy -- the recommended treatment for localized tumors -- when treated in hospitals that were early adopters of robotic surgery, according to a new study.

14 Dec 2014

Highly-paid doctors make more money by ordering multiple procedures for patients: UCLA

In results characterized as "very surprising," UCLA researchers found for the first time that higher-earning clinicians make more money by ordering more procedures and services per patient rather than by seeing more patients, which may not be in patients' best interest.

9 Dec 2014

Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Some infections after prostate biopsy due to drug-resistant Escherichia coli can be thwarted by simple rectal swab cultures prior to the procedure. The cultures test for antibiotic-resistant E. coli, and the findings are used to direct the selection of antimicrobial prophylaxis used for the procedure, according to Rhode Island Hospital researchers.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Study links poor semen quality to higher risk of various health conditions

A study of more than 9,000 men with fertility problems has revealed a correlation between the number of different defects in a man's semen and the likelihood that the man has other health problems.

6 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

4 Dec 2014

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects.

2 Dec 2014

Sanovas's endoscopic imaging platform recognized by Frost & Sullivan

Based on its recent analysis of the endoscopic imaging market, Frost & Sullivan recognizes Sanovas Inc. with the 2014 Global Frost & Sullivan Award for New Product Innovation Leadership. In a market where spiralling healthcare costs impact the entire spectrum of stakeholders, Sanovas's ground-breaking endoscopic platform, MicroCam, provides the functionality of a high-end, flexible endoscope without the accompanying cost and maintenance burden.

1 Dec 2014

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.

29 Nov 2014

Immune-suppressing protein may predict how patients respond to treatment

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

27 Nov 2014

Urology News and Research

Latest Urology News and Research

Signostics gets FDA 510k clearance for handheld bladder scanner

ArborMetrix's RegistryMetrix analytics platform selected for UNC's urology department

Study demonstrates that pelvic floor muscle training improves erectile function

New imaging technique measurably improves prostate cancer screening

FDA receives Actavis' NDA resubmission for cariprazine

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Laparoscopic radical cystectomy can lead to reliable, long-term cancer control

Olympus receives FDA clearance for Narrow Band Imaging

Study: Patients with operable kidney cancers more likely to have partial nephrectomy

Highly-paid doctors make more money by ordering multiple procedures for patients: UCLA

Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Study links poor semen quality to higher risk of various health conditions

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

Sanovas's endoscopic imaging platform recognized by Frost & Sullivan

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

Immune-suppressing protein may predict how patients respond to treatment

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in